Angiotensin II type 2 receptor in chronic kidney disease: The good side of angiotensin II?

Kidney International

Volumn 75, Issue 10, 2009, Pages 1006-1008

  Griffin, Karen A ^a   Bidani, Anil K ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; RAMIPRIL; TELMISARTAN;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; GLOMERULOPATHY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY INJURY; NEPHROTOXICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RECEPTOR UPREGULATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION;

EID: 66149189442     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.59     Document Type: Note

References (12)

1. Benndorf RA, Krebs C, Hirsch-Hoffmann B et al. Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice. Kidney Int 2009 ; 75 : 1039 - 1049.
2. Siragy HM. AT 1 and AT 2 receptor in the kidney: role in health and disease. Semin Nephrol 2004 ; 24 : 93 - 100.
3. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006 ; 1 : 1054 - 1065.
4. Kurtz TW, Griffin KA, Bidani AK et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: Blood pressure measurements in experimental animals: a statement for professionals from the subcommittee of professional and public education of the American Heart Association council on high blood pressure research. Hypertension 2005 ; 45 : 299 - 310.
5. Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006 ; 103 : 17985 -1 7990.
6. Chobanian AV, Bakris GL, B lack HR e t al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003 ; 289 : 2560 - 2572.
7. Griffin KA, Kramer H, Bidani AK. Adverse renal consequences of obesity. Am J Physiol 2008 ; 294 : F685 -F 696.
8. Loutzenhiser R, Griffin K, Williamson G, B idani A. Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanisms. Am J Physiol 2006 ; 290 : R1153 - R1167.
9. Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol 2008 ; 294 : F1 - F9.
10. Nishida M, Fujinaka H, Matsusaka T e t al. Absence of angiotensin II type 1 receptor in bone marrowderived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002 ; 110 : 1859 -1 868.
11. Kirton CA, Loutzenhiser R. Alterations in basal protein kinase C activity modulate renal afferent arteriolar myogenic reactivity. Am J Physiol 1998 ; 275 : H467 - H475.
12. Mann JF, Schmieder R E, McQueen M e t al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008 ; 372 : 547 - 553.